Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome - Polish Adult Leukemia Group (PALG) pilot study

Annals of Hematology

Volumn 87, Issue 5, 2008, Pages 361-367

  Hołowiecki, Jerzy ^a   Grosicki, Sebastian ^a   Kyrcz Krzemien, Sławomira ^a   Skotnicki, Aleksander B ^b   Piatkowska Jakubas, Beata ^b   Warzocha, Krzysztof ^c   Seferynska, Ilona ^c   Zdziarska, Barbara ^d  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Acute myeloid leukemia; AML; Fludarabine; Induction

Indexed keywords

CYTARABINE; DAUNORUBICIN; FLUDARABINE; MITOXANTRONE; THIOGUANOSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALOPECIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEART FAILURE; HUMAN; INFECTION; ISCHEMIA; KIDNEY FAILURE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER FAILURE; LIVER TOXICITY; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; OVERALL SURVIVAL; PILOT STUDY; POLYNEUROPATHY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PILOT PROJECTS; POLAND; REMISSION INDUCTION; VIDARABINE;

EID: 41549129049     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0421-4     Document Type: Article

References (27)

1. Gandhi V (1993) Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma 11:7-13
2. Santana VM, Hurvitz CA, Blakley RL, Crom WR, Luo X, Roberts WM, Ribeiro R, Mahmoud H, Krance RA (1994) Complete hematologic remissions induced by 2-chlorodeioxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237-1242
3. Gandhi V, Plunkett W (1992) Cell cycle-specific metabolism of arabinosyl nucleosides in K 562 human leukemia cells. Cancer Chemother Pharmacol 31:11-17
4. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264
5. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E (1996) Clinical and laboratory srudies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 24:1563-1569
6. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with myelogenous leukemia during therapy. J Clin Oncol 11:116-124
7. Ahlmann M, Lanvers C, Lumkemann K, Rossig C, Freund A, Baumann M, Boos J (2001) Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells. Leukemia 15:69-73
8. Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 83:696-703
9. Russo D, Pricolo G, Michieli M, Michelutti A, Raspadori D, Bertone A, Marin L, Pierri I, Bucalossi A, Zuffa E, De Vivo A, Mazza P, Gobbi M, Lauria F, Zaccaria A, Baccarani M (2001) Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leuk Lymphoma 40:335-443
10. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M (1996) High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81:513-520
11. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P et al (1994) FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 8:1842-1846
12. Wrzesien-Kus A, Robak T, Lech-Maranda E, Wierzbowska A, Dmoszynska A, Kowal M, Holowiecki J, Kyrcz-Krzemien S, Grosicki S, Maj S, Hellmann A, Skotnicki A, Jedrzejczak W, Kuliczkowski K; Polish Adult Leukemia Group (2003) A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). Eur J Haematol 71:155-162
13. Robak T, Wrzesien-Kus A, Lech-Maranda E, Kowal M, Dmoszynska A (2000) Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 39:121-129
14. Wrzesien-Kus A, Robak T, Wierzbowska A, Lech-Maranda E, Pluta A, Wawrzyniak E, Krawczynska A, Kuliczkowski K, Mazur G, Kiebinski M, Dmoszynska A, Wach M, Hellmann A, Baran W, Holowiecki J, Kyrcz-Krzemien S, Grosicki S; Polish Adult Leukemia Group (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: A report of the Polish Adult Leukemia Group. Ann Hematol 84:557-564
15. Holowiecki J, Robak T, Kyrcz-Krzemien S, Grosicki S, Hellmann A, Skotnicki A, Jedrzejczak W, Konopka L, Giebel S, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J (2002) Daunorubicin, cytarabine, and 2-CdA (DAC-7) for remission induction in "de novo" adult acute myeloid leukaemia patients. Acta Haematol Pol 33:839-847
16. Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18:989-997
17. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, LoCocco F; International Working Group for Diagnosis, Standardization of Response Criteria (2003) Treatment outcomes, and reporting standards for therapeutic trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649
18. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 96:4075-4083
19. Adkins JC, Peters DH, Markham A (1997) Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005-1037
20. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ (1990) Fludarabine therapy in macroglobulinemic lymphoma. Blood 75:1928-1931
21. Warrell RP Jr, Berman E (1986) Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79
22. Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, Candoni A, Russo D, Fanin R, Baccarani M (1997) Effect of fludarabine and arabinosylcytosine on multidrug resistant cells. Haematologica 82:143-147
23. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9:343-350
24. te Boekhorst PA, Lowenberg B, Sonneveld P (1994) Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: Effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 8:1480-1486
25. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S et al (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671-678
26. Dillman RO, Davis RB, Green M, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C (1991) A comparative study of two different doses of cytarabin for acute myeloid leukaemia: A phase III trial of Cancer and Leukemia Group B. Blood 78:2520-2526
27. Weick JK, Kopecky TJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previosly untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood 88:2841-2951